English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/244932
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Highly Efficient T2 Cobalt Ferrite Nanoparticles Vectorized for Internalization in Cancer Cells

AuthorsMazarío, Eva; Cañete, Magdalena; Herranz, Fernando CSIC ORCID; Sánchez-Marcos, Jorge; Fuente, Jesús M. de la; Herrasti, Pilar; Menéndez, Nieves
Contrast agent
Cobalt ferrite
Folic acid
Issue Date2021
PublisherMultidisciplinary Digital Publishing Institute
CitationPharmaceuticals 14 : 124 (2021)
AbstractUniform cobalt ferrite nanoparticles have been synthesized using an electrochemical synthesis method in aqueous media. Their colloidal, magnetic, and relaxometric properties have been analyzed. The novelty of this synthesis relies on the use of iron and cobalt foils as precursors, which assures the reproducibility of the iron and cobalt ratio in the structure. A stable and biocompatible targeting conjugate nanoparticle-folic acid (NP-FA) was developed that was capable of targeting FA receptor positivity in HeLa (human cervical cancer) cancer cells. The biocompatibility of NP-FA was assessed in vitro in HeLa cells using the MTT assay, and morphological analysis of the cytoskeleton was performed. A high level of NP-FA binding to HeLa cells was confirmed through qualitative in vitro targeting studies. A value of 479 Fe+Co mM􀀀1s􀀀1 of transverse relaxivity (r2) was obtained in colloidal suspension. In addition, in vitro analysis in HeLa cells also showed an important effect in negative T2 contrast. Therefore, the results show that NP-FA can be a potential biomaterial for use in bio medical trials, especially as a contrast agent in magnetic resonance imaging (MRI).
Publisher version (URL)https://doi.org/10.3390/ ph14020124
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
pharmaceuticals-14-00124-v2.pdfArtículo principal3,27 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.